Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. Materials and MethodsIDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation.ResultsWe established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC50 of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV+propidium iodide–cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. ConclusionThese results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas.
Abstract
Purpose Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. Materials and MethodsIDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation.ResultsWe established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC50 of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV+propidium iodide–cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. ConclusionThese results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas.
참고문헌 (26)
- Louis DN, "The 2016 World Health Organization classification of tumors of the central nervous system : a summary", Acta Neuropathol, 131, pp.803~820 (2016)
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
- Stupp R, "Current and future developments in the use of temozolomide for the treatment of brain tumours", Lancet Oncol, 2, pp.552~560 (2001)
- Dang L, "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate", Nature, 462, pp.739~744 (2009)
- "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity", Sci Transl Med, 9, pp.eaal2463~ (2017)
- Parsons DW, "An integrated genomic analysis of human glioblastoma multiforme", Science, 321, pp.1807~1812 (2008)
- Cancer Genome Atlas Research Network, "Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas", N Engl J Med, 372, pp.2481~2498 (2015)
- SongTao Q, "IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma", Cancer Sci, 103, pp.269~273 (2012)
- Ohba S, "Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance", Cancer Res, 74, pp.4836~4844 (2014)
- Matsuoka S, "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro", Proc Natl Acad Sci U S A, 97, pp.10389~10394 (2000)
- Helleday T, "DNA repair pathways as targets for cancer therapy", Nat Rev Cancer, 8, pp.193~204 (2008)
- Lin L, "The Interleukin-33", ST2axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation, 2020, pp.12, 1685~1703
- Stupp R, "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial", Lancet Oncol, 10, pp.459~466 (2009)
- Lin L, "Recent advances in targeted therapy for glioma", Curr Med Chem, 24, pp.1365~1381 (2017)
- Yan H, "IDH1 and IDH2 mutations in gliomas", N Engl J Med, 360, pp.765~773 (2009)
- Horbinski C, "What do we know about IDH1", 2 mutations so far, and how do we use it?, 2013, pp.125, 621~636
- Cai J, "Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas", Oncotarget, 7, pp.16384~16395 (2016)
- Cai J, "ATRX mRNA expression combined with IDH1", 2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors : evidence from the whole transcriptome sequencing of 169 samples samples, 2014, pp.5, 2551~2561
- Lu Y, "Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair", Cancer Res, 77, pp.1709~1718 (2017)
- Inoue S, "Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2", Cancer Cell, 30, pp.337~348 (2016)
- Cairncross JG, "Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH", J Clin Oncol, 32, pp.783~790 (2014)
- Yang P, "IDH mutation and MGMT promoter methylation in glioblastoma : results of a prospective registry", Oncotarget, 6, pp.40896~40906 (2015)
- Knizhnik AV, "Survival and death strategies in glioma cells : autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage", PLoS One, 8, pp.e55665~ (2013)
- Quiros S, "Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles", Cell Cycle, 9, pp.168~178 (2010)
- Burma S, "ATM phosphorylates histone H2AX in response to DNA doublestrand breaks", J Biol Chem, 276, pp.42462~42467 (2001)
- Han B, "Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma", Cancer Lett, 419, pp.280~290 (2018)